EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Analyst Ratings
Canada - TSX:EPRX - CA29842P1053 - Common Stock
7.99 CAD
+0.24 (+3.1%)
ChartMill assigns a Buy % Consensus number of 84% to EPRX.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.22. This target is 40.43% above the current price.
EPRX.CA was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about EPRX.CA.
In the previous month the buy percentage consensus was at a similar level.
EPRX.CA was analyzed by 9 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-08 | Canaccord Capital | Downgrade | Buy |
| 2022-11-01 | Raymond James Capital | Upgrade | Outperform |
| 2022-06-09 | Raymond James Capital | Initiate | Outperform |
| 2022-04-21 | Canaccord Capital | Downgrade | Buy |
| 2022-04-01 | Raymond James Capital | Initiate | Outperform |
| 2021-11-12 | RaymondJamesFinancial | Downgrade | Outperform |
| 2021-08-18 | Canaccord Genuity | Downgrade | Buy |
| 2021-08-17 | Raymond James Financial | Initiate | Outperform |
EUPRAXIA PHARMACEUTICALS INC / EPRX.CA FAQ
Can you provide the average price target for EUPRAXIA PHARMACEUTICALS INC stock?
9 analysts have analysed EPRX.CA and the average price target is 11.22 CAD. This implies a price increase of 40.43% is expected in the next year compared to the current price of 7.99.
How do analysts rate EUPRAXIA PHARMACEUTICALS INC (EPRX.CA)?
The consensus rating for EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is 84.4444 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed EUPRAXIA PHARMACEUTICALS INC (EPRX.CA)?
The number of analysts covering EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is 9.